Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy

Journal of the American Veterinary Medical Association

Volumn 218, Issue 8, 2001, Pages 1275-1280

  Sirinarumitr, Kaitkanoke ^d   Johnston, Shirley D ^b   Root Kustritz, Margaret V ^c   Johnston, Gary R ^b   Sarkar, Dipak K ^a   Memon, Mushtaq A ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d KASETSART UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SAFETY; ECHOGRAPHY; NONHUMAN; ORGAN SIZE; PROSTATE HYPERTROPHY; SEMEN ANALYSIS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 0035871296     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2001.218.1275     Document Type: Article

References (42)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-471.
3. Laroque PA, Prahalada S, Noblot SM, et al. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate 1995;27:121-128.
4. Hornbuckle WE, MacCoy DM, Allan GS, et al. Prostatic disease in the dog. Cornell Vet 1978;68(suppl):284-305.
5. Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 1995;22:285-290.
6. Krawiec DR, Heflin D. Study of prostatic disease in dogs: 177 cases (1981-1986). J Am Vet Med Assoc 1992;200:1119-1122.
7. Lee C. Role of androgen in prostate growth and regression: stromal-epithelial interaction Prostate 1996;6(suppl):52-56.
8. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237-246.
9. Bard DR, Lasnitzki I. The influence of oestradiol on the metabolism of androgens by human prostatic tissue. J Endocrinol 1974;74:1-9.
10. Isaacs JT, Coffey DS. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 1981;108:445-453.
11. Lloyd JW, Thomas JA, Mawhinney MG. Androgens and estrogen in the plasma and prostatic tissue of normal dogs and dogs with benign prostatic hypertrophy. Invest Urol 1975;13:220-222.
12. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126:1165-1172.
13. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
14. Basinger RR. Surgical management of prostatic diseases. Compend Contin Educ Pract Vet 1987;9:993-999.
15. Basinger RR, Robinette CL, Hardie EM, et al. The prostate. In: Slatter D, ed. Textbook of small animal surgery. 2nd ed. Philadelphia: WB Saunders Co, 1993;1349-1367.
16. Barsanti JA. Diseases of the prostate gland, in Proceedings. Annu Meet Soc Theriogenol 1997;71-80.
17. Bamberg-Thalen B, Linde-Forsberg C. Treatment of canine benign prostatic hyperplasia with medroxyprogesterone acetate. J Am Anim Hosp Assoc 1993;29:221-226.
18. Wright PJ, Stelmasiak T, Black D, et al. Medroxyprogesterone acetate and reproductive processes in male dogs. Aust Vet J 1979;55:437-438.
19. Juniewicz E, McCarthy M, Lemp BM, et al. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs. Endocrinology 1990;126:2625-2634.
20. Nakayama O, Hirosumi J, Chida S, et al. FRI46687, a novel steroid 5α-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate 1997;31:241-249.
21. Span PN, Schalken JA, Sweep FGJ, et al. Identification and partial characterization of two steroid 5α-reductase isozymes in the canine prostate. Prostate 1998;34:222-230.
22. Rhodes L. The role of dihydrotestosterone in prostate physiology: comparison among rats, dogs and primates, in Proceedings. Annu Meet Soc Theriogenol 1996;124-135.
23. Cohen SM, Werrmann JG, Rasmusson GH, et al. Comparison of the effects of new specific azasteroid inhibitors of steroid 5α-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 1995;26:55-71.
24. Wilson JD. Role of dihydrotestosterone in androgen action. Prostate 1996;6(suppl):88-92.
25. Liang T, Cascieri MA, Cheung AH, et al. Species difference in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology 1985;117:571-579.
26. The finasteride study group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
27. Iguer-Ouada M, Verstegen JP. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs. J Reprod Fertil 1997;51(suppl):139-149.
28. Laroque PA, Prahalada S, Gordon LR, et al. Effects of chronic oral administration of a selective 5α-reductase inhibitor, finasteride, on the dog prostate. Prostate 1994;24:93-100.
29. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995;46:631-637.
30. Kamolpatana K, Johnston SD, Hardy S, et al. Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs. Am J Vet Res 1998;59:762-764.
31. Feeney DA, Johnston GR, Klausner JS, et al. Canine prostatic disease - comparison of radiographic appearance with morphologic and microbiologic findings: 30 cases (1981-1985). J Am Vet Med Assoc 1987;190:1018-1026.
32. Feeney DA, Johnston GR, Osborne CA, et al. Maximum-distention retrograde urethrocystography in healthy male dogs: occurrence and radiographic appearance of urethroprostatic reflux. Am J Vet Res 1984;45:948-952.
33. Feeney DA, Johnston GR, Klausner JS, et al. Canine prostatic disease - comparison of ultrasonographic appearance with morphologic and microbiologic findings: 30 cases (1981-1985). J Am Vet Med Assoc 1987;190:1027-1034.
34. Wheaton LG, de Klerk DP, Standberg JD, et al. Relationship of seminal volume to size and disease of the prostate in the beagle. Am J Vet Res 1979;40:1325-1328.
35. Ling GV, Branam JE, Ruby AL, et al. Canine prostatic fluid: techniques of collection, quantitative bacterial culture, and interpretation of results. J Am Vet Med Assoc 1983;183:201-206.
36. Kamolpatana K, Johnston GR, Johnston SD. Determination of canine prostatic volume using transabdominal ultrasonography. Vet Radiol Ultrasound 2000;41:73-77.
37. Olson PN, Wrigley RH, Thrall MA, et al. Disorders of the canine prostate gland: pathogenesis, diagnosis, and medical therapy. Compend Contin Educ Pract Vet 1987;9:613-623.
38. Johnston SD. Performing a complete canine semen evaluation in a small animal hospital. Vet Clin North Am Small Anim Pract 1991;21:545-551.
39. Kustritz MVR, Olson PN, Johnston SD. The effects of stain and investigators on assessment of morphology of canine sperm. J Am Anim Hosp Assoc 1998;34:348-352.
40. Cochran RC, Ewing LL, Niswender GD. Serum levels of follicular stimulating hormone, luteinizing hormone, prolactin, testosterone, 5α-dihydrotestosterone, 5α-androstane-3α, 17β-diol, and 17β-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia. Invest Urol 1981;19:142-147.
41. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons Inc, 1973;26-64.
42. Rittmaster RG, Manning AP, Wright AS, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 α-reductase inhibitor finasteride. Endocrinology 1995;136:741-748.